Quantum Cyber N.V. QUCY

QUCY Company Overview

Mainz Biomed N.V. is a molecular diagnostics company focused on the development and commercialization of non-invasive, DNA-based screening tests for the early detection of cancer. The company operates within the biotechnology and in‑vitro diagnostics industries, with a primary emphasis on colorectal cancer screening and the broader field of precision molecular diagnostics. Its core value proposition is improving early cancer detection through stool‑based and blood‑based molecular testing that can be integrated into existing clinical workflows.

The company’s principal commercial product is ColoAlert, a stool‑based colorectal cancer screening test that detects molecular biomarkers associated with cancer and advanced adenomas. Mainz Biomed positions itself as a developer of cost‑effective, laboratory‑friendly diagnostics that leverage established PCR‑based technologies rather than proprietary hardware. The company was founded in 2008 and has evolved from a research‑oriented diagnostics developer into a publicly listed company following its business combination and listing on Nasdaq under the ticker MYNZ.